PIM kinase inhibitors are emerging as a new class of cancer therapeutics, and the prevalence of increased PIM kinases expression across different cancer types suggests that PIM inhibitors may be a treatment modality for a variety of cancer [14]. This evidence concerns the gene PIM1 and cancer.